Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Douglas  Johnson

Douglas Johnson, M.D., M.S.C.I.

Assistant Professor of Medicine
Hematologist/Oncologist

  • Appointments
    615-935-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Division of Hematology/Oncology
    (615) 322-4967

    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    615-936-3524
  • Faxes
    Division of Hematology/Oncology Fax
    (615) 343-7602
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    615-343-7602
  • Addresses
    Clinic
    1301 Medical Center Drive
    1710 The Vanderbilt Clinic
    Nashville, TN 37232

    Division of Hematology/Oncology
    2220 Pierce Ave, 777 PRB
    Nashville, TN 37232-6307
    Website

    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    777 Preston Research Building
    2220 Pierce Avenue
    Nashville, TN 37232
Profile

Dr. Johnson is a medical oncologist specializing in melanoma skin cancer and renal cell carcinoma. After receiving his MD from University of Alabama at Birmingham, he completed residency at Duke University followed by fellowship at Vanderbilt. He is also a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt.
Read more...

Dr. Johnson is a medical oncologist specializing in melanoma skin cancer and renal cell carcinoma. After receiving his MD from University of Alabama at Birmingham, he completed residency at Duke University followed by fellowship at Vanderbilt. He is also a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt. 

Dr. Johnson's research interests are in developing more effective immune therapies and genetically-targeted treatments for patients with cancer. He is the principle investigator for several melanoma clinical trials at Vanderbilt.

Education
  • M.D., University of Alabama at Birmingham
  • Residency, Duke University
  • Fellowship, Vanderbilt University
  • M.S.C.I., Vanderbilt University
 
Publications
  • Cohen DN, Lawson SK, Shaver AC, Du L, Nguyen HP, He Q, Johnson DB, Lumbang WA, Moody BR, Prescott JL, Chandra PK, Boyd AS, Zwerner JP, Robbins JB, Tyring SK, Rady PL, Chappell JD, Shyr Y, Infante JR, Sosman JA. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clin. Cancer Res [print-electronic]. 2015 Jun 6/1/2015; 21(11): 2624-34. PMID: 25724524, PMCID: PMC4452444, PII: 1078-0432.CCR-14-2667, DOI: 10.1158/1078-0432.CCR-14-2667, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25724524.
  • Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res [print-electronic]. 2015 May; 3(5): 464-9. PMID: 25649350, PMCID: PMC4420706, PII: 2326-6066.CIR-14-0217, DOI: 10.1158/2326-6066.CIR-14-0217, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25649350.
  • Thota R, Johnson DB, Sosman JA. Trametinib in the treatment of melanoma. Expert Opin Biol Ther [print-electronic]. 2015 May; 15(5): 735-47. PMID: 25812921, DOI: 10.1517/14712598.2015.1026323, ISSN: 1744-7682.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25812921.
  • Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol. 2015 Apr; 16(4): 15. PMID: 25796376, DOI: 10.1007/s11864-015-0330-z, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25796376.
  • Ohri N, Duan F, Machtay M, Gorelick JJ, Snyder BS, Alavi A, Siegel BA, Johnson DW, Bradley JD, DeNittis A, Werner-Wasik M. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. J. Natl. Cancer Inst [electronic-print]. 2015 Apr; 107(4): PMID: 25688115, PMCID: PMC4402361, PII: djv004, DOI: 10.1093/jnci/djv004, ISSN: 1460-2105.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25688115.
  • Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015 Mar; 3(3): 288-95. PMID: 25736262, PMCID: PMC4351797, PII: 3/3/288, DOI: 10.1158/2326-6066.CIR-14-0207, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25736262.
  • Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar; 7(2): 97-106. PMID: 25755682, PMCID: PMC4346215, PII: 10.1177_1758834014567469, DOI: 10.1177/1758834014567469, ISSN: 1758-8340.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25755682.
  • Jiang W, Jia P, Hutchinson KE, Johnson DB, Sosman JA, Zhao Z. Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget. 2015 Feb 2/10/2015; 6(4): 2496-508. PMID: 25537510, PMCID: PMC4385866, PII: 2954, DOI: 10.18632/oncotarget.2954, ISSN: 1949-2553.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25537510.
  • Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25600339.
  • Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J. Clin. Oncol [print-electronic]. 2014 Nov 11/20/2014; 32(33): 3697-704. PMID: 25287827, PMCID: PMC4226803, PII: JCO.2014.57.3535, DOI: 10.1200/JCO.2014.57.3535, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25287827.
  • Stevens PL, Johnson DB, Thompson MA, Keedy VL, Frangoul HA, Snyder KM. Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature. Case Rep Oncol Med [print-electronic]. 2014; 2014: 341980. PMID: 25328733, PMCID: PMC4190830, DOI: 10.1155/2014/341980, ISSN: 2090-6706.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25328733.